원발군날개수술 후 베바시주맙 결막하 주사의 효과
Effects of Subconjunctival Bevacizumab Injection after Primary Pterygium Surgery
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
목적: 원발성 군날개절제술 후 베바시주맙을 주사하여 그 효과와 안전성을 알아보고자 하였다. 대상과 방법: 2019년 12월부터 2021년 7월까지 원발성 군날개 환자 128명 136안을 대상으로 군날개절제술 후 자가윤부결막이식술을시행하였고, 베바시주맙군(80명 82안)에서는 수술 후 1주 후 베바시주맙 2.5 mg (0.1 mL)을 결막하 주사하였으며, 대조군(48명 54안)에서는 시행하지 않았다. 수술 후 1일째, 일주일, 1개월, 3개월, 6개월, 12개월 경과 관찰하여 두 군에서 군날개의 재발률을 비교하였다. 결과: 베바시주맙군에서 1안(1.21%)에서 재발하였으며 대조군에서 5안(9.25%)에서 재발하였다. 또한 베바시주맙군에서 섬유혈관 조직의 증식이 억제되는 양상을 보였으며 수술 후 합병증은 관찰되지 않았다. 결론: 군날개수술 베바시주맙 결막하 주사는 군날개 재발을 억제하는데 효과가 있어 수술 후의 보조요법으로 잠재력이 있다고 생각한다.
Abstract
Purpose: This study evaluated the efficacy and safety of subconjunctival bevacizumab injection after primary pterygium surgery. Methods: We performed a conjunctivo-limbal autograft after pterygium resection in 136 eyes of 128 patients with primary pterygium between December 2019 and July 2021. A subconjunctival bevacizumab injection of 2.5 mg (0.1 mL) was administered in the bevacizumab group but not in the control group (54 eyes of 48 patients). We compared pterygium recurrence rates between the two groups at 1 day, 1 week, 1 month, 3 months, 6 months, and 12 months after surgery. Results: Pterygium recurrence occurred in one eye (1.21%) in the bevacizumab group and five eyes (9.25%) in the control group. Additionally, fibrovascular tissue proliferation was suppressed in the bevacizumab group and no postoperative complications were observed. Conclusions: Pterygium recurrence occurred in one eye (1.21%) in the bevacizumab group and five eyes (9.25%) in the control group. Additionally, fibrovascular tissue proliferation was suppressed in the bevacizumab group and no postoperative complications were observed.
참고문헌 (29)
- Donnenfeld ED, "Subconjunctival mitomycin C as adjunctive therapy before pterygium excision", Ophthalmology, 110, pp.1012~1016 (2003)
- Chu WK, "Pterygium : new insights", Eye(Lond), 34, pp.1047~1050 (2020)
- Threlfall TJ, "Sun exposure and pterygium of the eye : a dose-response curve", Am J Ophthalmol, 128, pp.280~287 (1999)
- 김동익, "자가결막편 이식술을 이용한 원발성 군날개 수술의 임상성적", 대한안과학회지, 56(6), pp.856~862 (2015), 대한안과학회
- Hirst LW, "The treatment of pterygium", Surv Ophthalmol, 48, pp.145~180 (2003)
- Kaufman SC, "Options and adjuvants in surgery for pterygium : a report by the American Academy of Ophthalmology", Ophthalmology, 120, pp.201~208 (2013)
- Young AL, "A randomised trial comparing 0.02% mitomycin C and limbal conjunctival autograft after excision of primary pterygium", Br J Ophthalmol, 88, pp.995~997 (2004)
- Razeghinejad MR, "Preliminary results of subconjunctival bevacizumab in primary pterygium excision", Ophthalmic Res, 43, pp.134~138 (2010)
- Shenasi A, "Subconjunctival bevacizumab immediately after excision of primary pterygium : the first clinical trial", Cornea, 30, pp.1219~1222 (2011)
- Tan DT, "Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision", Arch Ophthalmol, 115, pp.1235~1240 (1997)
- 김창현, "원발성 군날개 환자에서 양막이식술, 자가결막이식술, 자가윤부결막이식술의 재발률 비교", 대한안과학회지, 50(12), pp.1780~1788 (2009), 대한안과학회
- Gazzard G, "Pterygium in Indonesia : prevalence, severity and risk factors", Br J Ophthalmol, 86, pp.1341~1346 (2002)
- 김경우, "재발성 군날개 환자에서 미세 다공성 신전된 폴리테트라플루오로에틸렌 삽입의 임상효과", 대한안과학회지, 54(3), pp.416~426 (2013), 대한안과학회
- Hacıoğlu D1, "Developments and current approaches in the treatment of pterygium", Int Ophthalmol, 37, pp.1073~1081 (2017)
- Lam DS, "Intraoperative mitomycin C to prevent recurrence of pterygium after excision : a 30-month follow-up study", Ophthalmology, 105, pp.901~904 (1998)
- 배성근, "양막이식술을 이용한 군날개 제거술에서 마이토마이신 C의 효과", 대한안과학회지, 53(2), pp.200~207 (2012), 대한안과학회
- Prabhasawat P, "Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium", Ophthalmology, 113, pp.1102~1109 (2006)
- Bekibele CO, "5-fluorouracil vs. beta-irradiation in the prevention of pterygium recurrence", Int J Clin Pract, 58, pp.920~923 (2004)
- Aspiotis M, "Angiogenesis in pterygium : study of microvessel density, vascular endothelial growth factor, and thrombospondin-1", Eye(Lond), 21, pp.1095~1101 (2007)
- Wilgus TA, "Regulation of scar formation by vascular endothelial growth factor", Lab Invest, 88, pp.579~590 (2008)
- Lazic R, "Intravitreally administered bevacizumab(Avastin)in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration", Graefes Arch Clin Exp Ophthalmol, 245, pp.68~73 (2007)
- Jorge R, "Intravitreal bevacizumab(Avastin)for persistent new vessels in diabetic retinopathy(IBEPE study)", Retina, 26, pp.1006~1013 (2006)
- Iliev ME, "Intravitreal bevacizumab(Avastin)in the treatment of neovascular glaucoma", Am J Ophthalmol, 142, pp.1054~1056 (2006)
- 서재신, "원발성군날개 수술 후 베바시주맙 결막하 주사의 효과", 대한안과학회지, 54(1), pp.53~59 (2013), 대한안과학회
- 이종욱, "재발성군날개 치료에 있어 항혈관내피성장인자 항체 베바시주맙을 적용한 임상효과", 대한안과학회지, 49(12), pp.1901~1909 (2008), 대한안과학회
- Fernandes M, "Outcome of pterygium surgery : analysis over 14 years", Eye(Lond), 19, pp.1182~1190 (2005)
- Yang HK, "Efficacy of bevacizumab injection after pterygium excision and limbal conjunctival autograft with limbal fixation suture", Graefes Arch Clin Exp Ophthalmol, 258, pp.1451~1457 (2020)
- Nava-Castañeda A, "Triple subconjunctival bevacizumab injection for early corneal recurrent pterygium : one-year follow-up", J Ocul Pharmacol Ther, 31, pp.106~113 (2015)
- Fallah MR, "Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium", Curr Eye Res, 35, pp.17~22 (2010)